LymphomaArchives
PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway
Lymphoma 7 min.
Diffuse large B cell lymphoma (DLBCL) is the most prevalent form of lymphoma among adults globally, accounting for approximately one-third of annual non-Hodgkin lymphoma (NHL) cases [1]. DLBCL demonstrates heterogeneity and aggressiveness, with high malignancy, rapid progression, and poor prognosis [2]....
The validation of advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in Turkish patients with classical Hodgkin lymphoma
Lymphoma 6 min.
Hodgkin lymphoma (HL) was first described in 1832 by Thomas Hodgkin, who reported seven patients with lymphadenopathy, splenomegaly, fever, night chills, and weight loss [1]. Many clinical prediction models have been developed to discriminate patients and provide the appropriate treatment since HL was...
CD5 and p53 immunohistochemistry: valuable prediction method in molecular typing of CD5-positive diffuse large B-cell lymphoma
Lymphoma 4 min.
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of non-Hodgkin’s lymphomas, making it the most common B-cell lymphoma [1]. Being an aggressive lymphoma, DLBCL comprising various subtypes, forming a diverse group of diseases with distinct clinical, pathological, and genetic...
Frequent association of malignant effusions in plasmablastic lymphoma: a single-institutional experience of nine cases in Taiwan
Lymphoma 3 min.
Plasmablastic lymphoma (PBL) is a rare, aggressive large B-cell lymphoma that is characterized by large atypical B cells with plasmablastic or immunoblastic morphology and a terminal B-cell differentiation phenotype – that is, the expression of plasma cell-related antigens (CD38, CD138, MUM1, PRDM1...
